Legend Biotech Corp (NASDAQ:LEGN) is set to release its Q3 2024 earnings on Nov 12, 2024. The consensus estimate for Q3 2024 ...

After losing some value lately, a hammer chart pattern has been formed for Legend Biotech (LEGN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on TScan Therapeutics (TCRX – Research ...

In a report released today, Sami Corwin from William Blair maintained a Hold rating on Legend Biotech (LEGN – Research Report). The ...

Legend Biotech Corporation (NASDAQ:LEGN) Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Ladies and gentlemen, ...

On Friday, Legend Biotech Corp (LEGN) stock saw a decline, ending the day at $40.03 which represents a decrease of $-0.92 or -2.25% from the prior close of $40.95. The stock opened at $40.61 and ...

NASDAQ:LEGN opened at $40.03 on Monday. The company has a current ratio of 4.84, a quick ratio of 4.78 and a debt-to-equity ratio of 0.25. Legend Biotech has a 1 year low of $38.60 and a 1 year ...

National Pension Service raised its stake in shares of Legend Biotech Co. (NASDAQ:LEGN – Free Report) by 4.3% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 23,535 shares of the ...

Detailed price information for Legend Biotech Corp ADR (LEGN-Q) from The Globe and Mail including charting and trades.

Johnson & Johnson shows strong progress in oncology with Darzalex sales and regulatory filings, leading to a 'Buy' rating ...

Detailed price information for Legend Biotech Corp ADR (LEGN-Q) from The Globe and Mail including charting and trades.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...